XSHE
300439
Market cap583mUSD
Oct 09, Last price
10.31CNY
1D
1.38%
1Q
21.87%
Jan 2017
-65.85%
IPO
-28.99%
Name
MedicalSystem Biotechnology Co Ltd
Chart & performance
P/E
62.69
P/S
2.59
EPS
0.16
Div yield, %
1.33%
Shrs. gr., 5y
0.51%
Rev. gr., 5y
-7.42%
Revenues
1.53b
-12.09%
Net income
63m
-75.50%
CFO
288m
-27.65%
Dividend
Jun 11, 20260.033 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Medicalsystem Biotechnology Co., Ltd. is a Chinese company focused on delivering clinical diagnostic solutions. Their comprehensive product line includes a full array of reagents and instruments designed for COVID-19 detection, such as PCR, antibody, and antigen test kits, alongside nucleic acid reagents. Beyond infectious disease diagnostics, the company also supplies advanced medical equipment like automated biochemistry analyzers (complete with their corresponding bio-reagents), hematology analyzers, urine analyzers, and glycated hemoglobin analyzers. Additionally, their offerings extend to Point-of-Care Testing (POCT) devices and cutting-edge chemiluminescence immunoassay analyzers. In addition to its diagnostic product offerings, Medicalsystem also provides healthcare services. Initially established in 2003 as Ningbo Medicalsystem Biotechnology Co., Ltd., the company officially adopted its current name, Medicalsystem Biotechnology Co., Ltd., in January 2017. Its corporate headquarters are situated in Ningbo, China.
Key people
Jihua Zou
General Manager, Director · since 2016
Liang Fang
Deputy General Manager · since 2017
Min Shen
Deputy General Manager · since 2018
Huiping Xiong
Chief Financial Officer, Deputy General Manager, Secretary of the Board · since 2018
Gaipeng Huang
Staff Elected Director · since 2025
Bingde Zou
Chairman of the Board · since 2016
Yunpeng Tian
Independent Director · since 2020
Ling Xu
Independent Director · since 2023
Headquarters & legal address
宁波市鄞州区启明南路299号
宁波市, ZJ 310000
CN
宁波市, ZJ 310000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||